UBS has cut its price target for Assembly Biosciences from $52 to $48 but still thinks it's a good buy.

Nov 3, 2026, 7:23 PM ETOpinionRead the original at marketscreener.com

Neutral

UBS cut its price target by $4 per share but kept its Buy rating. The mixed opinion reports no change to ASMB's business, so it does not change the company's outlook.

ASMB · Assembly Biosciences, Inc.

AI read · Neutral

The AI's read

This is UBS's view of ASMB's shares, not a report of changed sales, trial results, or company plans. The lower target points to a less favorable view, but the unchanged Buy rating points the other way. Together, they do not show a change in the company's outlook.

Get alerts for ASMB

Follow Assembly Biosciences, Inc. (ASMB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ASMB

Free on the App Store and Google Play, or on the web.